Quarterly report [Sections 13 or 15(d)]

Schedule of Accounts Payable (Details)

v3.25.1
Schedule of Accounts Payable (Details) - USD ($)
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable interest rate 100.00% 100.00%    
Other accounts payable $ 554,000 $ 453,000    
Total accounts payable 2,380,000 3,853,000    
Cytovance Biologics Inc [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable $ 600,000 [1] $ 1,183,000 [1] $ 1,984,000 $ 3,515,000
Accounts payable interest rate [1] 25.00% 31.00%    
University of Minnesota [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable $ 629,000 $ 712,000    
Accounts payable interest rate 26.00% 18.00%    
Legal Services Firm [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable $ 597,000 $ 1,505,000    
Accounts payable interest rate 25.00% 39.00%    
Other Accounts Payable [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accounts payable interest rate 24.00% 12.00%    
[1] Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock. See Note 7 – Commitments and Contingencies, Significant Agreements.